Dr. Rahul Khurana MD
Clinical Assistant Professor of Ophthalmology , THE REGENTS OF THE UNIVERSITY OF CALIFORNIA - CC
Member of the Healthcare Council
Council Member Biography
Rahul Khurana, MD, is a Vitreoretinal Surgeon at Northern California Retina Vitreous Associates Medical Group, one of the largest retina practices in the Bay Area. He is also a Clinical Assistant Professor of Ophthalmology at University of California San Francisco. Dr. Khurana is fellowship trained in Uveitis, Ocular Inflammation and Vitreoretinal disease. He has published over 40 peer reviewed papers, won numerous national awards and involved over nine clinical trials. Dr. Khurana's areas of expertise include retina, uveitis, and drug delivery. He has won research grants from Howard Hughes Medical Institute, Research to prevent blindness, and fight for sight. In 2007, Dr. Khurana was recognized by the American Medical Association as one of the top 51 emerging national leaders expected to make a strong impact on the future of medicine. (This is me - Update Profile)
Employment History
- 2009 - Unspecified
- Clinical Assistant Professor of Ophthalmology , THE REGENTS OF THE UNIVERSITY OF CALIFORNIA - CC
- 2009 - Unspecified
- Vitreoretinal Surgeon, NORTHERN CALIFORNIA RETINA VITREO
- 2007 - 2009
- Clinical Instructor- Retinal-Vitreoretinal Disease, Johns Hopkins University - CC
- Unspecified - 2007
- Clinical Instructor, UNIVERSITY OF SOUTHERN CALIFORNIA
GLG NewsSM Analyses by Rahul Khurana
GLG News is now G+ Insights
-
G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.
-
CATT Study Results will NOT Drastically affect Lucentis (Genentech, Roche) Usage
May 9, 2011
Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration | www.nejm.org
The much anticipated CATT study revealed equal efficacy of both Lucentis and Avastin in the management of Age-related Macular Degeneration at one year. Despite the dramatic cost differences in medications (40x fold), prescribing patterns for both Lucentis and Avastin are set and will not dramatically change. Other developments this year may influence practice patterns more.
-
Laser with Anti-VEGF Therapy maybe the New Standard for Diabetic Macular Edema.
May 3, 2010
Diabetic Macular Edema: Ranibizumab Injections Plus Laser Therapy Results in Dramatic Visual Improvement | www.sciencedaily.com
This large study by the National Eye Institute shows that combination laser therapy with Ranibizumab (Genentech, Roche) results in dramatic improvements in visual acuity in comparison to the gold standard treatment (laser alone) for diabetic macular edema (DME). The bar has been raised for DME; and this could affect future therapies involving steroids that are in the pipeline for DME.
-
Microplasmin may be a Less Invasive Therapeutic for Vitreoretinal Disorders.
April 21, 2010
ThromboGenics Announces that Microplasmin Meets Primary Endpoint in Phase III Trial for the Non-Surgical Treatment of Symptomatic Vitreomacular Adhesion | www.thrombogenics.com
ThromboGenics released Phase III Results showing that Microplasmin reached its primary endpoints of non-surgical resolution of focal vitreomacular adhesion. This novel non-surgical therapeutic could be an alternative to the more invasive vitrectomy to treat a variety of retinal diseases from macular holes to diabetic retinopathy.
-
Iluvien (PSDV) could be a Novel Treatment for Diabetic Macular Edema.
January 15, 2010
pSivida (PSDV) Reports Positive Iluvien FAME Phase III Results | www.streetinsider.com
Iluvien (pSivida) is a novel drug delivery technology which delivers an intraocular steroid to the back of the eye for up to three years. The Phase III data show that at 24 months Iluvien is an effective treatment in the management of diabetic macular edema. In addition to focal laser, Iluvien could be the next therapeutic for diabetic macular edema.
-
Ozurdex (AGN) may be a Big Loser for Vein Occlusion Management.
January 13, 2010
FDA Approval of Ozurdex Introduces a New Generation of Drug Delivery Therapy | www.drugs.com
Ozurdex (Allergan) was approved last summer as the first treatment for macular edema for central retinal vein occlusions. It utilized a novel drug delivery technology to prolong delivery of a steroid. However, recent results of the SCORE study and initial results from the CRUISE and BRAVO Trials (Genentech) are more impressive. The SCORE Study shows similiar efficacy at a fraction of the cost while the BRAVO and CRUISE Trials results are significantly better.
GLG Study Groups with Rahul Khurana(?)
| Study Group Name | No. Members |
|---|---|
| Ophthalmologists | 1708 |
| Ophthalmologists (US) | 1197 |
| Corneal and Refractive Ophthalmic Surgeons (US) | 541 |
| Physicians who Implant Intraocular Lenses | 248 |
| Ophthalmologists who Treat Macular Degeneration (US) | 216 |
GLG Live Meetings with Rahul Khurana(?)
Rahul Khurana has not participated in any GLG Live Meetings.
Gerson Lehrman Group, Inc. connects communities with knowledge through two distinct, yet complementary offerings: GLG Research and G+.